Duodenal Polyposis Classification in FAP

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-02-02

Study Completion Date

2030-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Duodenal cancer is the leading cause of cancer-related mortality in patients with familial adenomatous polyposis (FAP), yet the current Spigelman staging system provides limited predictive accuracy for advanced neoplasia. The DRACO study (Duodenal Risk Assessment in adenomatous polyposis Coli -Oncogene) is a multicenter, STROBE- and CONSORT-compliant cohort study that analyzes upper endoscopies from genetically confirmed FAP patients across independent cohorts to develop, validate, and externally test two multivariable risk models.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endoscopic Evaluation of Duodenal Polyposis in Patients With Familial Adenomatous Polyposis (FAP)

NCT03346980

Familial Adenomatous Polyposes Duodenal Polyposis Duodenal Cancer

COMPLETED

Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)

NCT02656134

Familial Adenomatous Polyposis

UNKNOWN

Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients

NCT00134758

Adenomatous Polyposis Coli, Familial

UNKNOWN PHASE2/PHASE3

Coxib-inhibition of Duodenal Polyp Growth in FAP

NCT00844727

Duodenal Polyposis

TERMINATED PHASE2/PHASE3

A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis

NCT04677998

Familial Adenomatous Polyposis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Duodenal cancers represent the leading cause of cancer-related mortality in individuals with familial adenomatous polyposis (FAP). While endoscopic surveillance is a critical component of duodenal cancer management, clinical decisions are primarily guided by the Spigelman staging system. Introduced in 1989, this framework stratifies patients into four stages based on duodenal polyp size, number, histology, and the grade of dysplasia.

Despite its widespread use, the Spigelman system was not originally designed to predict cancer incidence or progression and lacks formal validation for these outcomes. A recent systematic review and meta-analysis confirmed its limited sensitivity for detecting duodenal cancers, at approximately 50%, with even lower sensitivity for papillary cancer. This limitation in early cancer detection also constrains the identification of patients at elevated risk of malignant transformation during a window in which endoscopic intervention might still be feasible. As high-grade dysplasia (HGD) is a well-established precursor to adenocarcinoma and a valid therapeutic target, the inability of the current system to anticipate HGD and its progression to cancer can undermine opportunities for timely, minimally invasive intervention.

The current clinical paradigm reserves prophylactic surgery or intensified endoscopic therapy primarily for patients with Spigelman stage IV disease. However, both cancer and high-grade dysplasia frequently arise in patients with lower-stage disease. Given the already limited sensitivity of the Spigelman system for cancer detection, its sensitivity for predicting the development of HGD is likely even lower. Consequently, relying on a stage IV threshold may delay preventive intervention beyond the window of opportunity for feasible endoscopic management.

These limitations have led to a growing recognition of the need to revise the Spigelman classification system. Two broad strategies have been proposed to improve its clinical utility: reweighting the existing components to better reflect their prognostic contribution, or integrating patient-level variables, such as age and desmoid tumor status, to more accurately capture individual risk trajectories. Importantly, a staging system intended to guide endoscopic surveillance should prioritize prevention by informing timely intervention before malignant transformation occurs. Therefore, risk stratification must be grounded in the likelihood of developing pre-cancerous lesions, such as high-grade dysplasia, not solely on the risk of overt carcinoma. The DRACO study was designed to fill this gap in knowledge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Duodenum Cancer Familial Adenomatous Polyposis Duodenal Polyposis Ampulla of Vater Adenoma FAP Gene Mutation FAP Duodenal Neoplasms Duodenal Adenoma Ampulla of Vater Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Individuals with duodenal advanced neoplasia (Training cohort)

Individuals who developed biopsy-confirmed duodenal or ampullary high-grade dysplasia (HGD) or adenocarcinoma after the index EGD, within the training cohort (aka, cases)